The $300M offering is being conducted shortly after strong pipeline catalysts (ASCO data, Roche deal, NDA acceptance), suggesting the company is opportunistically raising capital at a premium to cash value. The immediate dilution pressure is the key near-term risk. Monitor the pricing of the offering relative to the $28.29 close on June 5, a discount greater than 5% would be particularly bearish. Watch for any insider participation as a mitigating signal.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 9 $28.07entry
- T+1 · 5mo ago −1.67%α −0.10% · $27.60
- T+5 · 5mo ago +7.70%α +5.28% · $30.23
- T+20 · 4mo ago +44.32%α +42.87% · $40.51
- T+60 · 3mo ago +43.11%α +39.29% · $40.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre-funded warrants, with an additional $45M greenshoe option. The offering comes on the heels of positive Phase 2/3 data for darovasertib in uveal melanoma presented at ASCO on June 1, a newly announced Roche collaboration for IDE892 in pancreatic cancer, and an NDA acceptance for review under the FDA's Real-Time Oncology Review program. The massive dilution (~12%+ at current share count, more with warrants exercised) is the dominant near-term factor, offsetting the positive pipeline catalysts and potentially capping upside.
Key Facts
- $300 million offering of common stock and pre-funded warrants
- Underwriters have option to purchase up to an additional $45 million of common stock
- Last reported stock price: $28.29 on June 5, 2026
- Net tangible book value as of March 31, 2026: $937.3 million, or $10.67 per share
- 87,856,154 shares outstanding as of March 31, 2026
- Proceeds for continued clinical development and potential commercialization of darovasertib for uveal melanoma, advancement of pipeline, and general corporate purposes
- Positive OptimUM-02 Phase 2/3 data presented June 1, 2026: darovasertib combination met primary endpoint with median PFS 6.9 months vs 3.1 months (HR: 0.42; p<0.0001)
- FDA agreed to review NDA for darovasertib under Real-Time Oncology Review program in April 2026; NDA filing expected H2 2026
- Roche clinical collaboration announced June 3, 2026 for IDE892 in MTAP-deleted pancreatic cancer
Financial Impact
$300M offering (plus up to $45M greenshoe) representing approximately 12-17% dilution to existing shareholders at the current ~88M share count, with additional dilution from pre-funded warrants
Risk Factors
- Immediate and substantial dilution to existing shareholders
- Dilution could be 12-17%+ depending on exercise of greenshoe and pre-funded warrants
- Proceeds use is at management's broad discretion with no specific M&A target identified
- Biotech market volatility may amplify the share price impact of a large secondary
- Pre-funded warrants have no public trading market and limited liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-261756 |
| Document: 0001193125-26-261756-index-headers.html | 0001193125-26-261756 |
| Document: 0001193125-26-261756-index.html | 0001193125-26-261756 |
| Document: 0001193125-26-261756.txt | 0001193125-26-261756 |
Track record
13 reports on IDYA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Viewing Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers